DuPont de Nemours, Inc. (DD) | The Buildout — AI Infrastructure
The Verdict
DuPont is a specialty advanced-materials company. It sells ion exchange resins, reverse-osmosis membranes and filtration systems into water treatment, including the ultrapure water that semiconductor fabs use. It also sells Tyvek medical packaging and protective garments, components for medical-device and biopharma customers, and building and industrial products such as insulation, adhesives and printing plates. It is not an AI pure-play: the AI-linked demand is a small niche inside Water, and management describes AI mainly as an internal productivity, R&D and sales tool rather than a revenue driver.
| Market Cap | — |
| Revenue (TTM) | $8.3B |
| Revenue Growth | −32.7% |
| EBITDA Margin (TTM) | 21.4% |
| Net Debt | $1.4B |
| Earnings Beats | 7 of 7 |
| P/E (TTM) | — |
| EV/EBITDA (TTM) | — |
What We Like
- Two consecutive guidance raises: FY2026 organic growth was raised again, and both the operating EBITDA and the adjusted EPS outlooks were raised too, with the net sales midpoint at $7.175B.
- A newly quantified productivity engine: 3% of COGS annual reduction targeted, against a history management calls 'flat at best.' Q2 delivered about 200 basis points of COGS reduction, worth about 100 basis points of margin.
- Semiconductor ultrapure water has grown 20%+ for several quarters, and microelectronics is about 20% of ion exchange resins.
- A new product line: direct lithium extraction, launched in Water with 'no capital required,' in a market management sizes at about $200M.
- Capital return: a $250M repurchase is set to launch in Q3 2026, following the $275M accelerated share repurchase announced in Q1 2026.
What We’re Watching
- Middle East: about $300M of exposure (roughly 4% of sales), a $10M first-quarter top-line hit, and guidance that assumes the disruption continues all year. Most regional water project revenue is expected in Q4 2026.
- Pricing retention: $90M of full-year pricing holds price/cost dollar-neutral, and about 2 points of the roughly 6% second-half organic guide is that pricing. Management declined to commit on 2027 if raw materials normalize.
- Healthcare & Water margin fell 30 basis points in Q2 on less favorable mix and growth investment — the question is whether that proves mix-driven or structural.
- PFAS: a North Carolina settlement surfaced after the Q2 call (2026-09-10), making the earlier 'no update' on the Q1 call a dormant-looking liability that later materialized.
The operating case is strengthening — two consecutive raises, a newly quantified productivity target, and broad-based demand across healthcare, aerospace, industrial water and semiconductors. The AI-infrastructure case is thin by contrast: the linked revenue is a water-treatment niche that is not a disclosed line and is estimated at about 1% of sales or less, and the computed criticality read is that chip fabs could qualify alternative suppliers within months. The open question is whether the productivity target lands within about 18 months and whether second-half pricing holds into 2027.
Earnings Beat
DuPont reported second-quarter 2026 net sales of $1.8B, up 4% on 4% organic growth, broad-based and led by healthcare, aerospace, industrial water and semiconductor markets. Gross margin was 35.1%. Operating EBITDA was $448M, up 8%, at a 24.6% margin — up 80 basis points year over year including a 30 basis point price/cost headwind. Adjusted EPS rose 21%, and transaction-adjusted free cash flow conversion reached 127%.
| Metric | Q2 FY2026 | Q1 FY2026 | Q2 FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $1.8B | $1.7B | $3.3B | −44.2% |
| Gross margin | 35.1% | 35.8% | 33.0% | +210bps |
| EBITDA | $324M | $254M | $825M | −60.7% |
| EPS | $1.04 | $1.17 | $0.42 | +147.1% |
| Transaction-adjusted FCF conversion | 127% | 65% | n/a | — |
On the water side, it's really providing ultra-pure water to the chip manufacturers. So that's where we saw the nice growth. I would say it was kind of up in the 20%-plus range where we've kind of seen it for the past several quarters and where we expect it to continue to grow… the AI revolution continues to take hold, we've got participation in the Water business with respect to the ultra-pure water opportunity.— Lori Koch, 2026-08-04
Management tone: Management's tone was confident and execution-oriented, and it moved toward operational specifics. Two consecutive quarters carried guidance raises, and the Q2 remarks said the company was 'again' raising full-year guidance. The quarter's strategic shift was trimming Water's full-year organic outlook on Middle East project timing, offset by Healthcare and Diversified Industrials; management framed it as timing rather than structure. New measurable frameworks appeared that were absent a quarter earlier: a 3%-of-COGS net productivity target, 80/20 moving from study to execution, and a compensation redesign. On AI, management said the higher commercial win rate was not driven by the AI work, which mainly improved speed to market.
Management Guidance
For FY2026, management guides a raised organic growth outlook, a net sales midpoint of $7.175B (lowered from $7.185B on a less favorable currency assumption), a raised operating EBITDA outlook embedding a 30 basis point oil-and-gas inflation headwind, a raised adjusted EPS outlook, and FCF conversion above 90%. For Q3 2026 it guides organic growth of about 5% adjusted for last year's timing shift (about 3% as reported), with currency a roughly 1% headwind. Price/cost is held dollar-neutral on $90M of full-year pricing, about 2 points of it in the second half. The guide assumes the Middle East situation continues through the remainder of the year.
Trajectory
The reported top line steps down sharply across the trailing quarters — $3,072M in Q3 FY2025, $1,693M in Q4 FY2025, $1,681M in Q1 FY2026, then $1,819M in Q2 FY2026. The step-down is portfolio, not demand: DuPont separated its Electronics business into Qnity (completed November 1, 2025) and divested Aramids (April 1, 2026), both now in discontinued operations. On the remaining base, management reports about 4% organic growth in both quarters and has raised guidance twice. Computed margin trends are mixed — gross margin expanding while operating and EBITDA margins compress.
The Model
The model projects FY+1 revenue of $7,195M and EBITDA of $1,770M, a 24.6% margin, and FY+2 revenue of $7,550M and EBITDA of $1,918M, a 25.4% margin. The near term tracks close to management's own FY2026 guidance — a net sales midpoint of $7.175B — with the margin held near 24.5%. FY+2 leans on the productivity program, targeted at 3% of COGS within about 18 months, and on the faster-growing niches: semiconductor ultrapure water at 20%+ and the new direct-lithium-extraction line.
| Metric | FY2025 | Next FY (E) | Following FY (E) |
|---|---|---|---|
| Revenue | $11.1B | $7.2B | $7.5B |
| YoY Growth | — | −35.1% | +4.9% |
| EBITDA | $2.8B | $1.8B | $1.9B |
| EBITDA Margin | 25.3% | 24.6% | 25.4% |
Projections are the median of 5 independent model runs. The model’s revenue sits 1.1% above analyst consensus.
For FY2026, management guides a raised organic growth outlook, a net sales midpoint of $7.175B (lowered from $7.185B on a less favorable currency assumption), a raised operating EBITDA outlook embedding a 30 basis point oil-and-gas inflation headwind, a raised adjusted EPS outlook, and FCF conversion above 90%. For Q3 2026 it guides organic growth of about 5% adjusted for last year's timing shift (about 3% as reported), with currency a roughly 1% headwind. Price/cost is held dollar-neutral on $90M of full-year pricing, about 2 points of it in the second half. The guide assumes the Middle East situation continues through the remainder of the year.
What Could Go Right — and Wrong
- A signed accretive deal in Water or Healthcare (packaging or CDMO) at the stated hurdle, which would move the portfolio toward management's stated two-thirds growth / one-third aspiration.
- Productivity landing ahead of the roughly 18-month clock, with COGS reduction beyond the about 200 basis points realized in Q2.
- Middle East water projects converting on schedule in Q4 2026, supporting Water's second-half step-up — management framed the earlier trim as timing, not structural.
- A commercial win for direct lithium extraction in a market management sizes at about $200M, with no capital required.
- A residential construction turn that compounds Building Technologies' claimed outperformance in a soft market.
- Pricing gives back: about 2 points of the roughly 6% second-half organic guide is the oil-and-gas surcharge, and management would not commit to keeping it if raw materials normalize.
- Middle East water projects slip out of Q4 2026 into 2027, concentrating execution risk in a single quarter.
- The Healthcare & Water margin contraction, down 30 basis points in Q2, proves structural rather than a mix swing.
- PFAS liability broadens beyond the North Carolina settlement that surfaced after the Q2 call (2026-09-10).
- The 80/20 program's resource reallocation costs more revenue than expected, offsetting its margin benefit.
Looking Ahead
Over the next 12 months the questions are whether the second-half organic acceleration converts — about 2 of the roughly 6 points is already-taken pricing — and whether the Middle East water projects land in Q4 2026 as guided. Management also points to a 3%-of-COGS productivity run rate within about 18 months, a few million dollars of 80/20 benefit in the second half, a $250M repurchase launching in Q3 2026, and an M&A pipeline in Water and Healthcare. A North Carolina PFAS settlement surfaced after the Q2 call (2026-09-10).
- Q3 2026Q3 2026 earnings — Tests organic growth near ~5% adjusted for last year's timing shift.
- 2H 202680/20 EBITDA benefit — Management expects a few million dollars of benefit in the half.
- Q4 2026Middle East water revenue — Most regional project revenue expected in Q4 rather than Q3.
- FY2026Free cash flow conversion — Company guides conversion above 90% (reaffirmed).
- ~18 months3% productivity run rate — Target is a 3% of COGS reduction on a net basis.
- 2027Commission-based sales force — Sales force moves to commission-based pay in 2027.
Financials
Annual Summary
| Metric | FY2024 | FY2025 | TTM | YoY |
|---|---|---|---|---|
| Revenue | $12.1B | $11.1B | $8.3B | -8.0% |
| Gross Margin | 32.0% | 32.9% | 34.4% | +90bps |
| EBITDA | $3.0B | $2.8B | $1.8B | -5.2% |
| EBITDA Margin | 24.5% | 25.3% | 21.4% | +75bps |
| Net Income | $704M | −$779M | $55M | -210.7% |
| Free Cash Flow | $1.3B | $1.1B | $1.1B | — |
| Net Cash | — | — | — | — |
Key Ratios (Trailing)
- P/E TTM—
- EV/EBITDA TTM—
- EV/Revenue TTM—
- Price/FCF TTM—
- Gross Margin (TTM)34.4%
- EBITDA Margin (TTM)21.4%
- Net Margin (TTM)0.7%
- ROIC6.3%
- FCF Conversion63.8%
- SBC / Revenue0.3%
The Company
DuPont is a specialty advanced-materials company serving healthcare, water, construction and industrial markets. Its Healthcare & Water Technologies segment sells Tyvek medical packaging and protective garments, Amberlite ion exchange resins, Filmtec reverse-osmosis and nanofiltration elements, and Inge and Itegratec ultrafiltration modules. Its Diversified Industrials segment sells Tyvek house wrap, Styrofoam insulation, Corian solid surface, Vespel parts, Molykote lubricants, Betaforce and Betaseal adhesives, and Cyrel printing plates. The AI link sits inside Water, where DuPont supplies ultrapure-water ion exchange resins and membranes to semiconductor fabs.
DuPont has just finished a multi-year reshaping. It separated its Electronics business into Qnity, completed November 1, 2025, which paid DuPont about $4.1 billion in cash. It divested Aramids to Arclin on April 1, 2026 for about $1.2 billion gross. A 1-for-3 reverse split completed in June 2026, and GICS moved the company to Industrials on July 31, 2026. Operations run on four frameworks — innovation excellence, commercial excellence, operational excellence and 80/20 — with a vitality index of about 35% and R&D targeted at about 2.5% of sales.
Business Segments
Competitive Landscape
The source material does not detail DuPont's competitive position. It places the company one to two steps upstream of the final application, selling resins, membranes, packaging and adhesives to industrial and municipal customers who carry the end-market brand. Management points to application development as the differentiator. For the AI-linked piece, the computed criticality read is that chip fabs could qualify alternative ultrapure-water resin and membrane suppliers within months.
- Toray (3402.T)Named in the derived relationship map; not discussed by the company.
- Lanxess (LXS.DE)Named in the derived relationship map; not discussed by the company.
- Ecolab (ECL)Named in the derived relationship map, where it appears as both a customer and a competitor. Not discussed by the company.
- Xylem (XYL)Named in the derived relationship map, where it appears as both a customer and a competitor. Not discussed by the company.
- 3M (MMM)Named in the derived relationship map; not discussed by the company.
Supply Chain
DuPont buys amines, industrial gases and specialty intermediates, then sells resins, membranes and packaging upstream of industrial and municipal end users. No neighbor transcript names DuPont, so the read on its demand environment is triangulated.
Related companies
See all Chip Making companies → · How this layer works: Chapter 1, The Chip →
More on DD: Earnings recap